English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Study Objective  Telavancin and vancomycin are both approved for treatment of hospital‐acquired and ventilator‐associated bacterial pneumonias caused by  Staphylococcus aureus , and both agents can cause renal dysfunction. The objective of this study was to assess renal function changes by performing renal shift table analyses of telavancin‐ and vancomycin‐treated patients in phase  III  trials.    Design  Retrospective, descriptive analysis of data from the safety population from the Assessment of Telavancin for Treatment of Hospital‐Acquired Pneumonia ( ATTAIN ) trials.    Patients  A total of 1503 adults with hospital‐acquired or ventilator‐associated bacterial pneumonia primarily caused by gram‐positive pathogens and who received telavancin (n = 751) or vancomycin (n = 752).    Measurements and Main Results  Decline or improvement in creatinine clearance (CrCl) across seven defined categories (≤30, >30–40, >40–50, >50–60, >60–70, >70–80, and >80 ml/min) was classified as negative or positive shifts, respectively. The number of categories crossed (either positive or negative) determined the grade of shift (of a potential grades 1–6, with crossing from one category to the next adjacent category defined as a grade 1 shift) at specific time points compared with baseline: day 4, day 7, and end of therapy ( EOT ). Approximately 77%–91.6% of patients had either no change or improvement of CrCl across all time points for both treatments. Negative shifts were consistent for telavancin (day 4, 19.3%; day 7, 19.0%;  EOT , 23.0%) but increased over time for vancomycin (day 4, 8.4%; day 7, 12.3%;  EOT , 19.3%). A significantly lower proportion of patients receiving vancomycin showed renal function decline on day 4 and day 7. At  EOT , negative shift rates were similar between treatments (treatment difference 3.6% [95% CI −0.7 to 7.9]). At day 7 and  EOT , a higher percentage of vancomycin‐treated patients experienced high‐grade negative shifts relative to telavancin (day 7, vancomycin 2.8% vs telavancin 1.9%;  EOT , vancomycin 4.7% vs telavancin 4.1%), though differences were not statistically significant.    Conclusion  Use of shift tables revealed differences in timing of renal function changes in patients receiving telavancin and vancomycin. Telavancin‐related declines in renal function were similar at day 4 and day 7, with a slight increase by  EOT . This differed from vancomycin, which caused a steady increase in the percentage of patients with renal function decline over time. A significant difference in negative renal shifts between treatments occurred at day 4 and day 7 and favored vancomycin; however, the difference was minimal and not significant at  EOT .

pharmacotherapy: the journal of human pharmacology and drug therapy

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the  ATTAIN  Trials